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Abstract
Background: Since 2001, several studies have reported high rifampicin resistance rates (45 - 100%) among
methicillin-resistant Staphylococcus aureus (MRSA) isolates from South Africa. The authors previously characterised
100 MRSA isolates from hospitals in Cape Town, South Africa; forty-five percent of these isolates were rifampicin-
resistant. The majority (44/45) corresponded to ST612-MRSA-IV, which is prevalent in South Africa, but has not been
reported frequently elsewhere. The remaining rifampicin-resistant isolate corresponded to ST5-MRSA-I. The aim of
this study was to investigate further the prevalence and genetic basis of rifampicin-resistance in MRSA isolates from
hospitals in Cape Town.
Results: Between July 2007 and June 2011, the prevalence of rifampicin-resistant MRSA in hospitals in Cape Town
ranged from 39.7% to 46.4%. Based on the results of the aforementioned study, nine ST612-MRSA-IV isolates, the
rifampicin-resistant ST5-MRSA-I isolate, and two rifampicin-susceptible MRSA isolates were investigated. Four
previously described ST612-MRSA-IV isolates, including two each from South Africa and Australia, were also
included.
The ST5-MRSA-I isolate carried a single mutational change, H481Y, commonly associated with high-level rifampicin
resistance. All ST612-MRSA-IV isolates carried an uncommon double amino acid substitution in RpoB, H481N, I527M,
whilst one of the Australian ST612-MRSA-IV isolates carried an additional mutation within rpoB, representing a
novel rpoB genotype: H481N, I527M, K579R. All ST612-MRSA-IV isolates also shared a unique silent single nucleotide
polymorphism (SNP) within rpoB.
Conclusions: That local ST612-MRSA-IV isolates described here share an uncommon rpoB genotype and a unique
silent SNP suggests this clone may have undergone clonal expansion in hospitals in Cape Town. Further, the data
suggest that these isolates may be related to rifampicin-resistant ST612-MRSA-IV previously described in South
Africa and Australia.
Background
It has long been acknowledged that antimicrobial use
drives the emergence of resistant pathogens [1]. Cur-
rently in South Africa, rifampicin is used primarily for
the treatment of tuberculosis, although it is also some-
times used in combination therapies to treat Staphylo-
coccus aureus infections. A national antimicrobial
susceptibility surveillance study carried out in South
Africa between 2005 and 2006 showed that 52.8% of
MRSA isolates from public diagnostic laboratories were
rifampicin-resistant [2]. Regional studies carried out
between 2001 and 2006 in public hospitals in the Kwa-
Zulu Natal and Gauteng provinces of South Africa
reported that 63 - 100% of MRSA isolates were rifampi-
cin-resistant [3,4]. Given South Africa’s high incidence
of tuberculosis and subsequent widespread use of rifam-
picin, it is likely that selective pressure has propelled the
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emergence and preponderance of rifampicin-resistant
MRSA in this country.
A recent study on the molecular characterisation of
MRSA from hospitals in Cape Town, South Africa,
showed that ST612-MRSA-IV, a previously infrequently
reported clone, was dominant in Cape Town hospitals
[5]. Of the 100 MRSA isolates included in that study, 45
were rifampicin-resistant. Moreover, ST612-MRSA-
IVaccounted for 44 of these rifampicin-resistant isolates.
The remaining rifampicin-resistant MRSA isolate corre-
sponded to ST5-MRSA-I. A recent national report on
MRSA clones circulating in South Africa indicated that
ST612-MRSA-IV was the most prevalent and wide-
spread clone [6]. However, whether these MRSA isolates
were resistant to rifampicin was not reported. Prior to
the Cape Town study [5] and the recently reported
national investigation [6], only four clinical ST612-
MRSA-IV isolates had been described, including two
each from South Africa and Australia, although the anti-
microbial susceptibility profiles of these isolates were
not reported [7-9].
Rifampicin is a bactericidal antimicrobial agent that
inhibits transcription by binding to the b-subunit of the
bacterial DNA-dependent RNA polymerase [10]. The b-
subunit of RNA polymerase is encoded by rpoB, and
mutations within conserved regions of the gene have
been shown to confer resistance to rifampicin in a num-
ber of bacteria, including S. aureus [10-12]. The majority
of mutations associated with rifampicin resistance in S.
aureus have been mapped to a conserved region of rpoB
known as the rifampicin resistance-determining region
(RRDR) [11-13].
The available information on rifampicin resistance
genotypes in S. aureus is restricted to a limited number
of studies [11-17], which, to the best of our knowledge,
have included only one isolate from South Africa [17].
This communication describes the prevalence and
genetic basis of rifampicin resistance in MRSA from
hospitals in Cape Town.
Methods
Setting and statistical analysis of laboratory data
The National Health Laboratory Service (NHLS) micro-
biology laboratory at Groote Schuur Hospital, Cape
Town, serves three tertiary- and two secondary-level
public hospitals situated within Cape Town. The labora-
tory data for all S. aureus isolates collected between July
2007 and June 2011 were retrieved from the NHLS
database. The isolates were stratified according to
methicillin and rifampicin susceptibilities. Differences
between proportions were analysed using the c2-test,
and the c2-test for trend was used to assess linear trends
over time [18].
Isolate selection
S. aureus isolates were identified either by the produc-
tion of DNAse, or on the VITEK 2 (bioMérieux, La
Balme-les-Grottes, France). The authors recently used a
combination of antimicrobial susceptibility testing,
pulsed-field gel electrophoresis (PFGE), SCCmec typing,
spa typing and multilocus sequence typing (MLST) to
characterise 100 MRSA isolates obtained from hospitals
in Cape Town between January 2007 and December
2008 [5]. The majority of the isolates were obtained
from two tertiary level facilities, Groote Schuur Hospital
(GSH) and Red Cross War Memorial Children’s Hospi-
tal (RCCH). Forty-five of the 100 isolates were rifampi-
cin-resistant (44 ST612-MRSA-IV and 1 ST5-MRSA-I)
[5].
Twelve of the previously characterised MRSA isolates
described above were selected for rpoB genotyping, and
their properties are shown in Table 1. Two ST612-
MRSA-IV isolates, one each from GSH and RCCH,
were selected from PFGE cluster D [5]. Both had spa
type t064, the only type detected in representative iso-
lates from this cluster [5]. Five ST612 MRSA-IV isolates,
from four of the five hospitals (Table 1), were selected
from the more genetically diverse PFGE cluster E [5].
Three spa types were identified in representative isolates
from cluster E, with t1443 most frequently detected.
Two of four sporadic ST612-MRSA-IV isolates were
included. These isolates were obtained from GSH and
RCCH, with one corresponding to spa type t1257,
which was not identified in any of the other ST612-
MRSA-IV isolates (Table 1) [5]. Also included were the
rifampicin-resistant ST5-MRSA-I and two rifampicin-
susceptible isolates (Table 1). Additionally, two ST612-
MRSA-IV from both South Africa (N83 and N84) [8]
and Australia (04-17052 and 09-15534) [9] were
included in the investigations (Table 1).
Antimicrobial susceptibility testing
The rifampicin and vancomycin MICs of the study iso-
lates were determined by E-test (bioMérieux, La Balme-
les-Grottes, France).
rpoB genotyping
A 702 bp region of rpoB spanning amino acid residues
441 to 673 (S. aureus co-ordinates), including the
RRDR, was amplified by PCR using primers designed by
Aubry-Damon et al. [11]. The PCR was carried out in a
final volume of 100 μl with 1X reaction buffer, 1.5 mM
MgCl2, 40 pmol of each primer and 400 μM of deoxy-
nucleotide triphosphates (Thermo Scientific, Wilming-
ton, DE, USA). One hundred nanograms of template
DNA and 1 U of Super Therm Taq DNA polymerase
(JMR Holdings, London, UK) were added to each reac-
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tion. Amplification was carried out using an Applied
Biosystems 2720 Thermocycler (Applied Biosystems,
Carlsbad, CA, USA). The PCR cycling conditions con-
sisted of an initial denaturation step at 94°C for 4 min,
followed by 35 cycles of denaturation at 94°C for 30 s,
annealing at 52°C for 45 s, elongation at 72°C for 45 s,
with a final extension step at 72°C for 3 min.
The 702 bp fragment was purified using the MinElute
Gel Extraction Kit (QIAGEN, Valencia, CA, USA), and
both strands were sequenced directly at the Central
Analytical Facility at the University of Stellenbosch. The
nucleotide sequences obtained were aligned to the rpoB
sequence of rifampicin-susceptible S. aureus strain
RN4220 (GenBank accession number: X64172) using
the ClustalW algorithm in BioEdit Sequence Alignment
Editor (version 7.0.5.2) [19].
Results
Antimicrobial susceptibility testing
The 14 rifampicin-resistant isolates expressed high-level
rifampicin resistance (rifampicin MICs ≥ 256 mg/L).
The remaining 2 isolates were confirmed to be rifampi-
cin-susceptible by E-test (rifampicin MICs ≤ 0.016 mg/
L), as was previously determined by disc diffusion or on
the VITEK 2 [5]. All 16 isolates were susceptible to van-
comycin; 15 had vancomycin MICs ≤ 1 mg/L and one
isolate, CT-C31-08 (ST5-MRSA-I), had a vancomycin
MIC of 2 mg/L.
Prevalence of rifampicin resistance among S. aureus
isolates from hospitals in Cape Town
The NHLS microbiology laboratory at Groote Schuur
Hospital carried out antimicrobial susceptibility testing
on 13 746 clinical S. aureus isolates between July 2007
and June 2011. MRSA accounted for 3298 (24%) of all
S. aureus isolates. Overall, 328 (3.1%) of the methicillin-
susceptible S. aureus (MSSA) isolates were resistant to
rifampicin, while 1432 (43.4%) of the MRSA isolates
were rifampicin-resistant (p < 0.0001). No significant
difference was detected in the prevalence of rifampicin
resistance among MRSA isolates over the four year per-
iod (p = 0.0521), as illustrated in Figure 1.
Identification of mutations in rpoB
The rpoB genotypes (GenBank accession numbers
JN593081 - JN593085) and other molecular characteris-
tics of the 16 isolates included in this investigation are
shown in Table 2. No amino acid substitutions were
observed in the RpoB protein sequences of the rifampi-
cin-susceptible isolates. The ST5-MRSA-I isolate carried
a single H481Y substitution known to confer high-level
rifampicin resistance [11,12] (Table 2). The nine ST612-
MRSA-IV isolates from hospitals in Cape Town all car-
ried the same double mutational changes within the
RRDR, H481N, I527M, which have also previously been
associated with high-level rifampicin resistance in S.
aureus [12,17]. N83 and N84, the ST612-MRSA-IV
Table 1 Characteristics of MRSA isolates selected for rpoB genotyping
Clonal type1 (isolate
name)
PFGE cluster2
(n)
spa
type
Rifampicin
phenotype3
Geographical
origin
Hospital4 (n)/Year of
isolation
Reference
ST612-MRSA-IV D (2) t064 Resistant Cape Town, RSA5 GSH (1), RCCH (1)/2008 [5]
ST612-MRSA-IV E (1) t064 Resistant Cape Town, RSA UCTPH/2008 [5]
ST612-MRSA-IV E (4) t1443 Resistant Cape Town, RSA GSH (2), RCCH (1), VH (1)/
2008
[5]
ST612-MRSA-IV Sporadic isolate
(1)
t1443 Resistant Cape Town, RSA GSH/2008 [5]
ST612-MRSA-IV Sporadic isolate
(1)
t1257 Resistant Cape Town, RSA RCCH/2008 [5]
ST5-MRSA-I C (1) t045 Resistant Cape Town, RSA MMH/2008 [5]
ST22-MRSA-IV Sporadic isolate
(1)
t032 Susceptible Cape Town, RSA GSH/2008 [5]
ST36-MRSA-II F (1) t021 Susceptible Cape Town, RSA GSH/2007 [5]
ST612-MRSA-IV (N83, N84) ND6 (2) t064 Resistant RSA Unknown/2004 - 2005 [8]
ST612-MRSA-IV (04-17052) ND (1) t064 Resistant Perth, Australia Unknown/2004 [9]
ST612-MRSA-IV (09-15534) ND (1) t7571 Resistant Perth, Australia Unknown/2009 [9]
1 Clonal types are indicated using the current international nomenclature (sequence type (ST) -antimicrobial phenotype - staphylococcal cassette chromosome
mec (SCCmec) type)
2 PFGE, pulsed-field gel electrophoresis
3 As determined by disc diffusion or on the VITEK 2
4 GSH, Groote Schuur Hospital; RCCH, Red Cross War Memorial Children’s Hospital; UCTPH, University of Cape Town Private Academic Hospital; VH, Victoria
Hospital; MMH, Mowbray Maternity Hospital
5 RSA, Republic of South Africa
6 ND, not determined
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isolates previously identified in South Africa, also carried
these changes. Similarly, the H481N, I527M double sub-
stitution was observed in 04-17052 and 09-15534, the
two ST612-MRSA-IV isolates from Australia; however,
an additional novel amino acid substitution, K579R, was
observed outside the RRDR in isolate 09-15534 (Table
2).
In addition to the mutations associated with amino
acid substitutions in RpoB, silent single nucleotide poly-
morphisms (SNPs) were detected in the rpoB sequences
of all 16 isolates (Table 2). Based on a comparison with
the corresponding sequence of the rifampicin-suscepti-
ble S. aureus strain RN4220, all isolates shared a com-
mon SNP at amino acid 498 (GCG ® GCT), as shown
in Table 2. Otherwise between one and three additional
SNPs particular to each clonal type were identified. Of
note is the conserved SNP at amino acid 512 (CGT ®
CGC), which was detected in all 13 ST612-MRSA-IV
isolates (Table 2).
Discussion
A number of factors drive the emergence and spread of
antibiotic resistance, including antibiotic usage, infection
control practices and the organism’s genetics [1]. Pre-
vious studies carried out in South Africa have reported
large proportions of rifampicin-resistant MRSA isolates
[2-5], and this study is no exception with the prevalence
of rifampicin-resistance among MRSA isolates ranging
from 39.7% to 46.4% (Figure 1). It is likely that the fre-
quent use of rifampicin to treat tuberculosis in South
Africa has driven the high prevalence of rifampicin-
resistance among local MRSA. Support for this sugges-
tion comes from the work of Sekiguchi et al. [14] who
reported a significantly higher prevalence of rifampicin-
resistant MRSA in tuberculosis wards compared to non-
tuberculosis wards in two hospitals in Japan.
A previous study showed that ST612-MRSA-IV was
the dominant clone circulating in public hospitals in
Cape Town. The 44 isolates corresponding to this clonal
type were uniformly resistant to rifampicin. Only one
other isolate of the 100 MRSA investigated was resistant
to this antibiotic and corresponded to ST5-MRSA-I [5].
Analysis of the RRDR of 14 rifampicin-resistant MRSA
(rifampicin MICs ≥ 256 mg/L), including the ST5-
MRSA-I isolate, nine representatives of Cape Town
ST612-MRSA-IV isolates and four previously described
ST612-MRSA-IV isolates, identified three rpoB geno-
types; no amino acid substitutions were detected in the
two rifampicin-susceptible isolates (rifampicin MICs ≤
0.016 mg/L) (Table 2).
The high-level rifampicin-resistant ST5-MRSA-I iso-
late carried a single mutational change within RpoB,
H481Y. This substitution, previously associated with
high-level resistance, is one of the most common rifam-
picin resistance genotypes and has been reported pre-
viously in several laboratory mutants and clinical
isolates [11-13,16,17]. Molecular modelling has demon-
strated that the H481Y substitution disrupts an H bond
between rifampicin and RNA polymerase, and also
reduces hydrophobic interactions within the binding
cavity, thereby decreasing the affinity of the drug for its
target [13].
A relatively uncommon genotype, H481N, I527M, pre-
viously reported in two clinical rifampicin-resistant
MRSA from Italy [12] and a single vancomycin inter-
mediate S. aureus (VISA) isolate from Brazil [17],
accounted for 12 of the 13 high-level rifampicin-resis-
tant ST612-MRSA-IV isolates, including N83, N84 and
04-17052. These results differ from the findings of Mick
et al. [15] who detected four markedly different rifampi-
cin resistance genotypes among 32 ST228-MRSA-IV
isolates, expressing various levels of resistance, which
were collected from a single hospital over three years.
The third rpoB genotype, H481N, I527M, K579R, was
present in 09-15534, the remaining Australian ST612-
MRSA-IV isolate. To the best of our knowledge, K579R,
which occurs outside the RRDR, has not been reported
previously, hence H481N, I527M, K579R represents a
novel rpoB genotype. Whether the latter substitution
impacts rifampicin resistance is unknown because the
RRDR of this isolate contains two other mutations asso-
ciated with resistance to this antibiotic. It is possible
that this novel K579R substitution represents the latest
mutational change in ST612-MRSA-IV as isolate 09-
15534 was isolated in 2009, whereas the other MRSA
strains included in this study were collected between
2004 and 2008.
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Figure 1 Annual percentage of rifampicin-resistant MRSA
isolates collected between July 2007 and June 2011. Figures
shown below the graph indicate the total number of MRSA isolates
obtained each year, or part thereof. No significant difference was
detected in the prevalence of rifampicin resistance among MRSA
isolates over the four year period (p = 0.0521).
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A number of silent SNPs were detected in the 16 iso-
lates when using the nucleotide sequence of RN4220 as
a reference (Table 2). One SNP at amino acid position
498 (GCG ® GCT) was common to all 16 isolates,
which belonged to four different S. aureus clonal com-
plexes (CCs) (Table 2). This SNP has also been reported
in ST247-MRSA-I control strains ATCCBAA44 and
PER88 (CC8), and in ST228-MRSA-I (CC5) isolates
from Spain [15]. Codon usage tables derived from gen-
ome sequences of six S. aureus control strains
(NCTC8325, COL, Newman, USA300, N315 and
Mu50), indicated that the codon GCT is twice as preva-
lent as GCG [20]. It is possible that the SNP arose on
separate occasions in multiple S. aureus lineages and
that its prevalence is related to codon bias in this organ-
ism. However, it seems more likely that RN4220 con-
tains the SNP (GCT ® GCG), which arose once in this
strain. This can only be confirmed when more rpoB
sequences of S. aureus isolates from a variety of genetic
backgrounds become available.
Of greater interest is the only other conserved silent
SNP found in the codon for arginine at amino acid posi-
tion 512 (CGT ® CGC) that was observed in all ST612-
MRSA-IV isolates (Table 2). This mutation was notable
for two reasons: firstly, AT-rich organisms such as S.
aureus more commonly favour AT-rich codons with
Table 2 Results of rifampicin susceptibility testing and rpoB genotyping
Clonal type1
(clonal complex)
PFGE cluster2 (n)/spa type (n) Isolate origin
(isolate name)
Rifampicin
MIC (mg/L)3
Amino acid
position4
Nucleotide
substitution
Amino acid
substitution
ST22- MRSA-IV (22) Sporadic isolate (1)/t032 (1) Cape Town, RSA5 ≤ 0.016 498 GCG ® GCT -
554 CAT ® CAC -
599 AAT ® AAC -
ST36- MRSA-II (30) F (1)/t021 (1) Cape Town, RSA ≤ 0.016 474 AAC ® AAT -
498 GCG ® GCT -
502 GTA ® GTG -
518 ACA ® ACG -
ST5- MRSA-I (5) C (1)/t045 (1) Cape Town, RSA ≥ 256 481 CAT ® TAT H481Y
498 GCG ® GCT -
630 AAT ® AAC -
658 GGT ® GGA -
ST612- MRSA-IV (8) D (2), E (5), sporadic isolates (2)/t064
(3), t1443 (5), t1257 (1)
Cape Town, RSA ≥ 256 481 CAT ® AAT H481N
498 GCG ® GCT -
512 CGT ® CGC -
527 ATT ® ATG I527M
ST612- MRSA-IV (8) ND6 (2)/t064 (2) RSA (N83; N84) ≥ 256 481 CAT ® AAT H481N
498 GCG ® GCT -
512 CGT ® CGC -
527 ATT ® ATG I527M
ST612- MRSA-IV (8) ND (1)/t064 (1) Australia (04-
17052)
≥ 256 481 CAT ® AAT H481N
498 GCG ® GCT -
512 CGT ® CGC -
527 ATT ® ATG I527M
ST612- MRSA-IV (8) ND (1)/t7571 (1) Australia (09-
15534)
≥ 256 481 CAT ® AAT H481N
498 GCG ® GCT -
512 CGT ® CGC -
527 ATT®ATG I527M
579 AAA®AGA K579R
1 Clonal types are indicated using the current international nomenclature (sequence type (ST) - antimicrobial phenotype - staphylococcal cassette chromosome
mec (SCCmec) type)
2 PFGE, pulsed-field gel electrophoresis
3 As determined by E-test
4 S. aureus co-ordinates
5 RSA, Republic of South Africa
6 ND, not determined
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either adenine or thymine bases, rather than cytosine, at
the third position [21,22]; secondly, codon usage tables
indicated that CGT is more common than CGC for
arginine [20]. Thus, it is possible to suggest that the
SNP (CGT ® CGC) has not arisen on multiple occa-
sions in ST612-MRSA-IV, but instead was inherited
from a common ancestor and has been conserved within
the lineage.
Interestingly, ST612-MRSA-IV has also recently been
reported as the predominant clone in a population of
horses in Australia [23]. All of the equine ST612-
MRSA-IV isolates that were tested were rifampicin-
resistant, making it tempting to speculate that they may
be related to those described in this study; however, the
equine strains carried SCCmec type IVa [23], while the
ST612-MRSA-IV isolates from Cape Town and Austra-
lia carried SCCmec type lished data), which suggests at
least two separate SCCmec acquisitions in this genetic
background.
Although mutations associated with resistance fre-
quently evince an initial fitness cost to the organism, it
has been shown that rifampicin-resistant E. coli do not
revert to wild-type susceptibility in the absence of this
antibiotic. Rather, they persist because of their capacity
to develop compensatory mutations, which restore bac-
terial fitness [24]. Other studies have also suggested that
the reduction of antibiotic pressure may not necessarily
result in reversion to susceptibility [25], which is worry-
ing in our setting given that ST612-MRSA-IV is multi-
drug-resistant [5].
Vancomycin remains the drug of choice for the treat-
ment of multidrug-resistant MRSA infections; however,
the emergence of vancomycin-resistant S. aureus poses
a new challenge. Watanabe et al. [17] have suggested
that certain mutational changes in rpoB, including
H481Y, may be linked to reduced vancomycin suscept-
ibility in S. aureus. In light of these facts, the vancomy-
cin MICs of isolates selected for rpoB genotyping in the
current study were determined by E-test. Interestingly,
the ST5-MRSA-I isolate, with rpoB genotype H481Y, was
susceptible to vancomycin (MIC of 2 mg/L). Of interest
is the observation that isolates with MICs of 2 mg/L
have been associated with a poor clinical response to
vancomycin [26]. All ST612-MRSA-IV were susceptible
to vancomycin (MICs of ≤ 1 mg/L), suggesting that the
mutational changes present in rpoB in these isolates are
not associated with resistance to vancomycin.
Conclusions
A subset of ST612-MRSA-IV isolates from Cape Town
hospitals, broadly representative of the total collection
with respect to molecular characteristics, as well as the
hospital of isolation, was selected to determine the
mechanism of rifampicin resistance in this clone.
Collectively, the data support a hypothesis of clonal
expansion of a rifampicin-resistant ST612-MRSA-IV
strain in local hospitals. The data also suggest that these
isolates may be related to rifampicin-resistant ST612-
MRSA-IV previously described in South Africa and Aus-
tralia. Studies including additional ST612-MRSA-IV iso-
lates collected from South Africa, Australia and the
United Kingdom are required to investigate further the
evolution of this clone.
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